2013 Poland Pharmaceuticals and Healthcare Market Report Q1

1
Poland Pharmaceuticals and Healthcare Report Q1
2013
http//www.rnrmarketresearch.com/poland-pharmaceut
icals-and-healthcare-report-q1-2013-market-report.
html
The Polish pharmaceutical market contracted
severely in 2012, owing to harsh pricingmeasures
and strict margins imposed on wholesalers,
pharmaceutical makers and retailers.
Moreover,over the course of the year, the burden
of pharmaceutical spending has shifted towards
the Polishconsumer, as the harsher reimbursement
regime has caused private contributions to
prescriptionpayments rise. We forecast a return
to growth in 2013, driven by private consumption
as the Polishgovernment entrenches cuts to drug
expenditure. We expect strong growth in the
medium to long term asPoland's economy
diversifies and aligns with developed countries.
The growth of private medicalcompanies is a
positive development in the Polish healthcare
market, and the possible introduction ofvoluntary
health insurance could lead.
2
Headline Expenditure Projections-
Pharmaceuticals PLN33.37bn (US11.26bn) in 2011
to PLN31.38bn (US9.62bn) in 2012-5.98 in local
currency terms and -14.5 in US dollar terms.-
Healthcare PLN112.18bn (US37.85bn) in 2011 to
PLN118.57bn (US36.37bn) in 20125.2 in local
currency terms and -5.5 in US dollar terms.-
Medical Devices PLN6.80bn (US2.29bn) in 2011 to
PLN7.10bn (US2.18bn) in 2012 4.5in local
currency terms and -5.0 in US dollar terms.
Local currency forecast has risen sinceQ412,
while the US dollar forecast has fallen.-
Risk/Reward Rating Poland has been overtaken by
Slovenia and Russia in our RRR rankings, owing
toworsening market conditions. Strict price
controls on drugs in addition to pay-back taxes
have seenPoland's ratings dip relative to
Slovenia. Poland's RRR score has decreased since
Q412, from 58.9 to56.9. The country's Industry
Rewards score has dipped from 53 to 47 owing to a
severe contraction in thesize of the market this
year. The Country Reward score remains unchanged
from Q412.   Request your sample copy _at_
http//www.rnrmarketresearch.com/contacts/request-
sample?rname65972
3
Key Trends And DevelopmentsThe number of
prescriptions receiving no subsidy at all from
the NFZ has increased significantly in
2012.Private healthcare spending in Poland is
expected to continue rising as incomes rise. The
role of theprivate sector and the potential
introduction of voluntary health insurance as a
supplement to the NFZsuggest market dynamics will
increasingly be driven by private
consumption.There is increasing
commercialisation and leasing of hospitals to
private healthcare providers by thegovernment,
aimed at turning around debt-ridden hospitals
back into profitability and introducingefficiency
measures.   Buy your report copy _at_
http//www.rnrmarketresearch.com/contacts/purchase
?rname65972
For More Details Contact sales_at_rnrmarketresearch
.com